Investigational Drug Information for Veliparib

What is the development status for investigational drug Veliparib?

Veliparib is an investigational drug.

There have been 96 clinical trials for Veliparib. The most recent clinical trial was a Phase 3 trial, which was initiated on August 5^th 2014.

The most common disease conditions in clinical trials are Carcinoma, Breast Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), AbbVie, and AbbVie (prior sponsor, Abbott).

Summary for Veliparib

US Patents	0
International Patents	0
US Patent Applications	2,640
WIPO Patent Applications	1,016
Japanese Patent Applications	140
Clinical Trial Progress	Phase 3 (2014-08-05)
Vendors	57

Recent Clinical Trials for Veliparib

Title	Sponsor	Phase
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer	AbbVie	Phase 1
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)	AHS Cancer Control Alberta	Phase 2
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer	Fudan University	Phase 2

See all Veliparib clinical trials

Clinical Trial Summary for Veliparib

Top disease conditions for Veliparib

Top clinical trial sponsors for Veliparib

See all Veliparib clinical trials

US Patents for Veliparib

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration

Veliparib Development Update and Market Projection

Last updated: February 17, 2026

Development Status

Veliparib (ABT-888) is an orally bioavailable PARP inhibitor developed by AbbVie, primarily targeting cancers with BRCA mutations and homologous recombination deficiency. Its development timeline includes multiple clinical trials, focusing on breast, ovarian, lung, and other solid tumors.

Clinical Trials and Approvals

• Phase 1/2: Demonstrated activity when combined with chemotherapies and immunotherapies. Trials showed manageable safety profiles.
• Combination Studies: Veliparib has been evaluated in combination with chemotherapy agents like temozolomide, cisplatin, and carboplatin, as well as immune checkpoint inhibitors.
• Regulatory Status: No regulatory approvals granted globally. Previously in accelerated review processes in certain regions; trials continue in specific indications.

Key Trials and Data

• A notable phase 2 trial in ovarian cancer combined Veliparib with chemotherapy, showing improved progression-free survival (PFS). However, phase 3 results in breast cancer (BRAVO trial) failed to meet primary endpoints on top-line analysis, limiting its progress toward approval in that indication.
• Trials continue assessing efficacy in combination therapies with immunotherapy, aiming to address resistance mechanisms.

Market Status and Competitive Landscape

Veliparib competes with other PARP inhibitors, including:

• Olaparib (Lynparza): Approved for ovarian and breast cancers.
• Niraparib (Zejula): Approved for ovarian cancer.
• Talazoparib (Talzenna): Approved for breast cancer.

Veliparib has yet to gain regulatory approval, partly due to inconsistent phase 3 outcomes and competition from established drugs.

Market Projection

The PARP inhibitor market is expanding rapidly, driven by increased adoption in ovarian, breast, and prostate cancers. Expected to reach approximately $7 billion by 2027, according to GlobalData.

Veliparib’s potential depends on successful trial outcomes and differentiation tactics:

• Target Indications: Focus on oncology subsets with high responsiveness, such as BRCA-mutated ovarian or prostate cancers.
• Combination Strategies: Potential for use with immunotherapy may unlock additional market segments.
• Regulatory Outlook: Without approvals, market entry remains uncertain; partnership or licensing deals could influence trajectory.

Market Entry Barriers

• Competition from approved PARP inhibitors with established clinical use.
• Uncertain efficacy results in late-stage trials.
• Price positioning compared to existing therapies.

Future Outlook

• Pending further clinical successes, Veliparib could penetrate niche markets, especially if combined with immunotherapy.
• Alternative development pathways, such as targeted indications or biomarker-driven use, may enhance prospects.
• Strategic alliances or licensing may accelerate market access.

Key Takeaways

• Veliparib's clinical development faces setbacks after mixed phase 3 results, particularly in breast cancer.
• The drug remains investigational without regulatory approval to date.
• The expanding PARP inhibitor market offers opportunities for future growth if trial outcomes and strategic partnerships favor success.
• Competition from established PARP inhibitors constrains potential market share.
• Critical factors for Veliparib include demonstrable efficacy in select indications and effective positioning within combination regimens.

FAQs

1. What is Veliparib primarily being developed for?
   It targets cancers with BRCA mutations, including ovarian and breast cancers, often in combination with chemotherapies or immunotherapies.

2. Has Veliparib received regulatory approval?
   No, it remains investigational, lacking approval in any jurisdiction.

3. How does Veliparib compare to other PARP inhibitors?
   It has shown promise in early trials but has not met primary endpoints in late-stage trials, limiting its competitive edge currently.

4. What factors could improve Veliparib’s market prospects?
   Successful trial outcomes in niche indications, effective combination therapies, and strategic partnerships.

5. When might Veliparib enter the market?
   If ongoing and future trials demonstrate sufficient efficacy and safety, regulatory submissions could occur within the next 2-4 years, contingent on positive results.

Citations

[1] GlobalData. PARP Inhibitors Market Analysis. 2023.